Abivax SA American Depositary Shares - Asset Resilience Ratio

Latest as of December 2025: 2.34%

Abivax SA American Depositary Shares (ABVX) has an Asset Resilience Ratio of 2.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Abivax SA American Depositary Shares debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$13.69 Million
Cash + Short-term Investments

Total Assets

$584.09 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Abivax SA American Depositary Shares's Asset Resilience Ratio has changed over time. See ABVX book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Abivax SA American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Abivax SA American Depositary Shares market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $13.69 Million 2.34%
Total Liquid Assets $13.69 Million 2.34%

Asset Resilience Insights

  • Limited Liquidity: Abivax SA American Depositary Shares maintains only 2.34% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Abivax SA American Depositary Shares Industry Peers by Asset Resilience Ratio

Compare Abivax SA American Depositary Shares's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for Abivax SA American Depositary Shares (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Abivax SA American Depositary Shares.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 2.34% $13.69 Million $584.09 Million +2.28pp
2024-12-31 0.07% $136.00K $205.23 Million -2.70pp
2023-12-31 2.77% $9.05 Million $327.06 Million +2.76pp
2022-12-31 0.01% $6.00K $75.54 Million +0.00pp
2021-12-31 0.01% $6.00K $109.23 Million 0.00pp
2020-12-31 0.01% $6.00K $71.30 Million 0.00pp
2019-12-31 0.01% $6.00K $51.73 Million -9.25pp
2018-12-31 9.26% $5.01 Million $54.05 Million -18.89pp
2017-12-31 28.15% $15.15 Million $53.81 Million +3.32pp
2016-12-31 24.84% $15.05 Million $60.60 Million +6.48pp
2015-12-31 18.36% $14.00 Million $76.27 Million +13.87pp
2014-12-31 4.49% $1.70 Million $37.97 Million +3.45pp
2013-12-31 1.04% $400.00K $38.46 Million --
pp = percentage points

About Abivax SA American Depositary Shares

NASDAQ:ABVX USA Biotechnology
Market Cap
$9.33 Billion
Market Cap Rank
#2345 Global
#837 in USA
Share Price
$117.61
Change (1 day)
+0.20%
52-Week Range
$5.67 - $145.31
All Time High
$145.31
About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more